| Literature DB >> 30248922 |
Akash Pandya1, Mark J Howard2, Mire Zloh3,4, Paul A Dalby5.
Abstract
Protein-based therapeutics are considered to be one of the most important classes of pharmaceuticals on the market. The growing need to prolong stability of high protein concentrations in liquid form has proven to be challenging. Therefore, significant effort is being made to design formulations which can enable the storage of these highly concentrated protein therapies for up to 2 years. Currently, the excipient selection approach involves empirical high-throughput screening, but does not reveal details on aggregation mechanisms or the molecular-level effects of the formulations under storage conditions. Computational modelling approaches have the potential to elucidate such mechanisms, and rapidly screen in silico prior to experimental testing. Nuclear Magnetic Resonance (NMR) spectroscopy can also provide complementary insights into excipient⁻protein interactions. This review will highlight the underpinning principles of molecular modelling and NMR spectroscopy. It will also discuss the advancements in the applications of computational and NMR approaches in investigating excipient⁻protein interactions.Entities:
Keywords: NMR; aggregation; excipients; formulation; molecular docking; molecular dynamics
Year: 2018 PMID: 30248922 PMCID: PMC6320905 DOI: 10.3390/pharmaceutics10040165
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
High throughput biophysical methods used for excipient screening.
| Biophysical Method | Details | Limitations | Application References |
|---|---|---|---|
| Raman spectroscopy | Measures shifts in energy (wavelength) of photons re-emitted after interaction with molecular vibrational modes. Provides an empirical signature of protein structure, that can be used to monitor changes in intramolecular dynamics and intermolecular interactions. | Low sensitivity. Out of the millions of incoming photons interacting with molecules, there is only one scattered Raman photon. | [ |
| Circular dichroism | Measures the difference in adsorption of circularly polarised light. Far-UV CD can determine the absolute and relative contributions of secondary structure types in proteins. Near UV CD can probe tertiary structure content. Can probe changes in protein structure in response to formulation. | A reference protein with known secondary structure is required to fit the experimental data. The quality of the fit also depends on the wavelengths used. | [ |
| Isothermal titration calorimetry (ITC) | Measures the heat emitted or absorbed during the titration of a protein with a ligand. The amount of heat indicates the proportion of excipient that binds the protein and its associated enthalpy. | ITC can be used to determine the excipient mechanism directly and indirectly. However, no structural information of the protein is given. | [ |
| Differential scanning calorimetry (DSC) | Routinely used in high-throughput screening of excipients for formulations. Determines the impact of excipients on the thermal stability of the protein, measured as the melting temperature and enthalpy of unfolding. | Useful for identifying excipients that preferentially interact with proteins, or that stabilise through crowding effects. Cannot be used to detect other mechanisms of action. Unable to characterise changes specific to the secondary or tertiary structure of proteins. | [ |
| Differential scanning fluorimetry (DSF) | Uses a PCR thermocycler to scan the fluorescence of extrinsic dye-binding to proteins as a function of temperature in microtitre plates, and determine their melting temperatures. | The excitation source of the PCR equipment can potential limit the type extrinsic fluorescence dyes used. Unable to characterise excipient mechanisms of action and can only detect tertiary structure changes. | [ |
Figure 1A schematic representation of the potential of in silico molecular docking, molecular dynamics simulation, and NMR spectroscopy to elucidate protein-excipient interactions to inform the rational design of protein-based formulations.
Figure 2A schematic of the molecular docking process on a single multimeric protein.
Figure 3A schematic of the molecular dynamics process.
The typical molecular dynamics (MD) simulations timescales that can observe various protein dynamics events.
| Protein Dynamics Event | MD Simulation Time Range |
|---|---|
| Vibrational motions | Femtoseconds (10−15) to picoseconds (10−12) |
| Rotational motions | Picoseconds (10−12) to nanoseconds (10−9) |
| Loop dynamics | Picoseconds (10−12) to milliseconds (10−3) |
| Ligand binding/unbinding | Nanoseconds (10−9) to seconds |
| Protein folding/unfolding | Microseconds (10−6) to seconds |
| Aggregation | Seconds and beyond |
Figure 4A schematic depicting the bacterial production of recombinant isotopically labelled protein, and recording of an NMR spectrum.
Figure 5(a) The NMR spectrum for a small molecule ligand will depict a narrow linewidth due to a longer transverse relaxation time. (b) In contrast, a protein has a shorter transverse relaxation time and thus a broad linewidth is shown. (c) TROSY prolongs the transverse relaxation times and thereby improves the protein signal in the spectrum.
Figure 6Schematic representation of saturation transfer difference (STD) NMR (a,b) adapted from [101] and WaterLOGSY (c) NMR. Increasing saturation of the ligand’s resonances is indicated by a colour gradient from blue (no saturation) to grey (high saturation).
Figure 7Binding hotspots for eight commercial excipients on the A33Fab surface. Reprinted from [156] with permission.